EBElisabet Balló

Elisabet Balló

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elisabet Balló has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-Term Effectiveness of Acetylsalicylic Acid in Primary Prevention of Cardiovascular Diseases and Mortality in Patients at High Risk, a Retrospective Cohort Study—The JOANA Study

    by Lia Alves-Cabratosa, Carles López, Maria Garcia-Gil, Èric Tornabell-Noguera, Marc Comas-Cufí, Jordi Blanch, Ruth Martí-Lluch, Anna Ponjoan, Gina Domínguez-Armengol, Lluís Zacarías-Pons, et al.

    Background/Objectives: Although differences seem to exist by age in primary cardiovascular prevention with acetylsalicylic acid (ASA), direct comparisons are lacking, as are studies with real-world data. We sought to examine the effectiveness of ASA in reducing cardiovascular diseases and overall mortality in patients at high risk by age subgroups. Methods: We designed a retrospective cohort study using the database of the Catalan primary care system (SIDIAP), Spain, for the period 2006–2020. Included participants were high-cardiovascular-risk individuals without previous vascular disease. We considered people aged 40 to 59 and ≥60 years of age. We assessed the incidences of atherosclerotic cardiovascular disease (ASCVD), all-cause mortality, and ASA adverse effects using Cox proportional hazards modelling, adjusted by the propensity score of ASA treatment. Results: During the study period, 7576 and 30,282 people were aged 40 to 59 and ≥60 years, respectively. The median follow-up was 11.21 (10.71–11.54) years (40 to 59 year-olds) and 11.09 (10.55–11.54) years (≥60 year-olds). The hazard ratio of ASA use for ASCVD in the group aged 40–59 years was 0.64 (0.41–0.99). The number needed to treat in this group was 40 persons and the number that needed to harm for gastrointestinal bleeding (the only adverse effect with significant hazard ratio) was 75 individuals. Conclusions: This direct comparison of real-world age groups at high cardiovascular risk showed no benefit but increased risk in the older population (≥60 years). In the younger subgroup, our observations would support primary prevention with ASA with a consideration of the individual optimal risk–benefit.

  • Open Access

    Individuals With SARS-CoV-2 Infection During the First and Second Waves in Catalonia, Spain: Retrospective Observational Study Using Daily Updated Data (Preprint)

    by Lia Alves-Cabratosa, Marc Comas-Cufí, Jordi Blanch, Ruth Martí-Lluch, Anna Ponjoan, Antoni Castro-Guardiola, Abelardo Hurtado-Ganoza, Ana Pérez-Jaén, Maria Rexach-Fumaña, Delfi Faixedas-Brunsoms, et al.

    BACKGROUND A description of individuals with SARS-CoV-2 infection comparing the first and second waves could help adapt health services to manage this highly transmissible infection. OBJECTIVE We aimed to describe the epidemiology of individuals with suspected SARS-CoV-2 infection, and the characteristics of patients with a positive test comparing the first and second waves in Catalonia, Spain. METHODS This study had 2 stages. First, we analyzed daily updated data on SARS-CoV-2 infection in individuals from Girona (Catalonia). Second, we compared 2 retrospective cohorts of patients with a positive reverse-transcription polymerase chain reaction or rapid antigen test for SARS-CoV-2. The severity of patients with a positive test was defined by their admission to hospital, admission to intermediate respiratory care, admission to the intensive care unit, or death. The first wave was from March 1, 2020, to June 24, 2020, and the second wave was from June 25, 2020, to December 8, 2020. RESULTS The numbers of tests and cases were lower in the first wave than in the second wave (26,096 tests and 3140 cases in the first wave versus 140,332 tests and 11,800 cases in the second wave), but the percentage of positive results was higher in the first wave than in the second wave (12.0% versus 8.4%). Among individuals with a positive diagnostic test, 818 needed hospitalization in the first wave and 680 in the second; however, the percentage of hospitalized individuals was higher in the first wave than in the second wave (26.1% versus 5.8%). The group that was not admitted to hospital included older people and those with a higher percentage of comorbidities in the first wave, whereas the characteristics of the groups admitted to hospital were more alike. CONCLUSIONS Screening systems for SARS-CoV-2 infection were scarce during the first wave, but were more adequate during the second wave, reflecting the usefulness of surveillance systems to detect a high number of asymptomatic infected individuals and their contacts, to help control this pandemic. The characteristics of individuals with SARS-CoV-2 infection in the first and second waves differed substantially; individuals in the first wave were older and had a worse health condition.

  • Open Access

    Hospitalization and 30-day fatality in 121,263 COVID-19 outpatient cases

    by Daniel Prieto-Alhambra, Elisabet Balló, Ermengol Coma, Núria Mora, María Aragón, Albert Prats-Uribe, Francesc Fina, Mència Benítez, Carolina Guiriguet, Mireia Fàbregas, et al.

    Background: To date, characterisation studies of COVID-19 have focussed on hospitalised or intensive care patients. We report for the first time on the natural history of COVID-19 disease from first diagnosis, including both outpatient and hospital care. Methods: Data was obtained from SIDIAP, a primary care records database covering >6 million people (>80% of the population of Catalonia), linked to COVID-19 RT-PCR tests, hospital emergency and inpatient, and mortality registers. All participants >=15 years, diagnosed with COVID-19 in outpatient between 15th March and 24th April 2020 (10 th April for outcome studies) were included. Baseline characteristics, testing, and 30-day outcomes (hospitalisation for COVID-19 and all-cause fatality) were analysed. Results: A total of 121,263 and 95,467 COVID-19 patients were identified for characterisation and outcome studies, respectively. Women (57.8%) and age 45-54 (20.2%) were predominant. 44,709 were tested, with 32,976 (73.8%) PCR+. From 95,467 cases, a 14.6% [14.4–14.9] were hospitalised in the month after diagnosis, with male predominance (19.2% vs 11.3%), peaking at age 75-84. Overall 30-day fatality was 4.0% [95%CI 3.9%-4.2%], higher in men (4.8%) than women (3.4%), increasing with age, and highest in those residing in nursing homes (25.3% [24.2% to 26.4%]). Conclusions: COVID-19 is seen in all age-sex strata, but severe forms of disease cluster in older men and nursing home residents. Although initially managed in primary care, 15% of cases require hospitalization within a month, with overall fatality of 4%.